Comment
doi: 10.1126/science.1096161.
Policy rebuttal. HIV vaccine trial justified
Affiliations
- PMID: 14963313
- DOI: 10.1126/science.1096161
Item in Clipboard
Comment
Policy rebuttal. HIV vaccine trial justified
Science.
.
No abstract available
Comment in
-
Thailand's Prime-Boost HIV Vaccine Phase III.Science. 2004 Feb 13;303(5660):954-5. doi: 10.1126/science.303.5660.954c. Science. 2004. PMID: 14963308 No abstract available.
-
Support for the RV144 HIV vaccine trial.Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. doi: 10.1126/science.305.5681.177b. Science. 2004. PMID: 15247455 No abstract available.
-
Outstanding questions on HIV vaccine trial.Science. 2004 Jul 9;305(5681):180; author reply 180. doi: 10.1126/science.305.5681.180a. Science. 2004. PMID: 15247456 No abstract available.
-
Support for the RV144 HIV vaccine trial.Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. Science. 2004. PMID: 15250069 No abstract available.
Comment on
-
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620. Science. 2004. PMID: 14726576 No abstract available.
Similar articles
-
Thailand's Prime-Boost HIV Vaccine Phase III.Science. 2004 Feb 13;303(5660):954-5. doi: 10.1126/science.303.5660.954c. Science. 2004. PMID: 14963308 No abstract available.
-
Support for the RV144 HIV vaccine trial.Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. doi: 10.1126/science.305.5681.177b. Science. 2004. PMID: 15247455 No abstract available.
-
Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.J Infect Dis. 2006 Dec 15;194(12):1625-7. doi: 10.1086/509263. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109331 No abstract available.
-
Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary.AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S141-3. AIDS Res Hum Retroviruses. 1994. PMID: 7865289 Review. No abstract available.
-
HIV/AIDS vaccines: 2007.Clin Pharmacol Ther. 2007 Dec;82(6):686-93. doi: 10.1038/sj.clpt.6100408. Epub 2007 Oct 31. Clin Pharmacol Ther. 2007. PMID: 17971817 Review.
Cited by
-
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.J Virol. 2006 Apr;80(8):3732-42. doi: 10.1128/JVI.80.8.3732-3742.2006. J Virol. 2006. PMID: 16571790 Free PMC article.
-
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.Curr HIV Res. 2013 Jul;11(5):427-38. doi: 10.2174/1570162x113116660064. Curr HIV Res. 2013. PMID: 24191938 Free PMC article.
-
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.J Infect Dis. 2011 Apr 1;203(7):969-75. doi: 10.1093/infdis/jiq152. J Infect Dis. 2011. PMID: 21402548 Free PMC article.
-
Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Arch Virol. 2012 Jan;157(1):1-20. doi: 10.1007/s00705-011-1145-2. Epub 2011 Oct 20. Arch Virol. 2012. PMID: 22012269 Free PMC article. Review.
-
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.J Virol. 2013 Feb;87(3):1708-19. doi: 10.1128/JVI.02544-12. Epub 2012 Nov 21. J Virol. 2013. PMID: 23175374 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
